<DOC>
	<DOCNO>NCT01476449</DOCNO>
	<brief_summary>This study see whether treat diabetic retinal swell ranibizumab injection eye monthly well treat diabetic retinal swell ranibizumab injection eye less frequently .</brief_summary>
	<brief_title>Dosing Study Ranibizumab Diabetic Retinal Macular Edema</brief_title>
	<detailed_description>This prospective randomized study compare two group patient diabetic macular edema . One group receive injection ranibizumab monthly group option receive injection ranibizumab less frequently . That eligible receive injection less frequently few injection give patient group well .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Patient relate consideration Phakic pseudophakic patient know history diabetes eligible . Women reproductive age require take urine pregnancy test prior administration study drug . Disease related consideration : Patients meet standard , accept diagnostic criterion diabetes currently treat least one systemic antihyperglycemic insulin medication . Patients BCVA ETDRS Snellenequivalent less equal 20/40 Central foveal thickness SDOCT &gt; 300um Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Foveal ischemia IVFA Intraocular surgery le 6 month ago Epiretinal membrane clinical significance Prior vitrectomy Uncontrolled glaucoma Macular peripheral laser within 90 Days Day 0 injection Intravitreal steroid injection within 90 day Day 0 injection Intravitreal systemic antiVEGF within 30 day Day 0 injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetic Retinal Swelling</keyword>
	<keyword>DIabetic Eye Disease</keyword>
</DOC>